Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,018.39 -17.30 (-0.34%) Dow
37,903.29 +87.37 (+0.23%) Nasdaq
15,605.48 -52.34 (-0.33%) Bitcoin USD
56,789.92 -2,973.01 (-4.97%) CMC Crypto 200
1,195.78 -143.29 (-10.70%)
Incyte Corporation (INCY)
After hours:
| Previous close | 52.05 |
| Open | 51.87 |
| Bid | 52.89 x 200 |
| Ask | 52.97 x 200 |
| Day's range | 51.82 - 53.98 |
| 52-week range | 50.27 - 69.83 |
| Volume | |
| Avg. volume | 1,847,373 |
| Market cap | 11.887B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 16.04 |
| EPS (TTM) | 3.30 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 72.94 |
Insider MonkeyIncyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript April 30, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $0.746 EPS, expectations were $0.88. INCY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to Incyte First […]
ZacksIncyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
- Reuters
Incyte misses quarterly profit on weak sales of lead drug
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade. During the first quarter, the Delaware-based company gained worldwide exclusive global rights for Monjuvi, approved by the FDA for the treatment of certain kinds of blood cancer, from MorphoSys AG.
